First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

por Mackie, Alison, Rascher, Juliane, Schmid, Marion, Endriss, Verena, Brand, Tobias, Seibold, Wolfgang
Publicado 2021

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic f...

por Goss, Christopher H., Jain, Raksha, Seibold, Wolfgang, Picard, Anne-Caroline, Hsu, Ming-Chi, Gupta, Abhya, Fajac, Isabelle
Publicado 2020

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study

por Goss, Christopher H., Fajac, Isabelle, Jain, Raksha, Seibold, Wolfgang, Gupta, Abhya, Hsu, Ming-Chi, Sutharsan, Sivagurunathan, Davies, Jane C., Mall, Marcus A.
Publicado 2022